
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis Inc. operates in the promising field of autoimmune disorder treatments with a robust pipeline that includes multiple drug candidates, potentially leading to significant market opportunities. The company projects peak sales of $2 billion for its lead product in systemic lupus erythematosus (SLE) with a conservative 20% probability of FDA approval, reflecting a strong anticipated financial impact if successful. Additionally, positive results from pivotal studies in related indications, such as psoriatic arthritis, suggest a broadening potential for revenue generation beyond just SLE.
Bears say
The negative outlook on Alumis Inc. is largely attributed to several critical risks within its development pipeline, notably related to its leading candidate, ESK-001. These risks encompass the potential inability to advance ESK-001 into pivotal trials punctually, as well as the possibility of the treatment failing to demonstrate significant efficacy in psoriasis (PsO) and systemic lupus erythematosus (SLE). Furthermore, delays in regulatory submissions and approvals in major markets, coupled with strong competition in the immunology and inflammation (I&I) sector, contribute additional uncertainty regarding the company's future market performance and viability.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares